title: Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis.
authors.forename: Markku
authors.initials: M
authors.lastname: Hakala
authors.forename: Kai
authors.initials: K
authors.lastname: Immonen
authors.forename: Markku
authors.initials: M
authors.lastname: Korpela
authors.forename: Mikko
authors.initials: M
authors.lastname: Vasala
authors.forename: Markku J
authors.initials: MJ
authors.lastname: Kauppi
mesh_terms: D000328:Adult; D000686:Amyloidosis / Q000150:complications* / Q000188:drug therapy*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000150:complications* / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; C502936:tocilizumab